RBC Capital Reiterates Outperform on Spruce Biosciences, Maintains $8 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Gregory Renza has reiterated an 'Outperform' rating on Spruce Biosciences (NASDAQ:SPRB), maintaining a price target of $8.
August 15, 2023 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital's reiteration of an 'Outperform' rating and maintenance of an $8 price target could positively influence Spruce Biosciences' stock in the short term.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. Given that RBC Capital has reiterated an 'Outperform' rating and maintained an $8 price target for Spruce Biosciences, this could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100